Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.671
C. Song, Wen Liu, Jing Wang, Jing Liang
Technique The main objective of this study is to analyze the expression levels of messenger ribonucleic acid and long non-coding ribonucleic acid in patients with platelet transfusion refractoriness and reveal the mechanism of T lymphocytes in immune platelet transfusion refractoriness. The Agilent expression profile chip was used to detect the expression levels; gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis were performed on the differential genes to determine their main biological functions. Unsupervised hierarchical clustering was used to process differential genes and the differential genes among samples were represented in a heat map. The differentially expressed messenger ribonucleic acids and long non-coding ribonucleic acids in different groups were found as 720 and 1719 in normal control group vs. platelet transfusion effective group; 4254 and 12491 in normal control group vs. platelet transfusion ineffective group and 1806 and 6216 in platelet transfusion effective group vs. platelet transfusion ineffective group. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis were performed on differentially expressed genes, and the results were annotated to be related to T cells. The co-expression of the target gene Ras-related protein 1A and long non-coding transactive response deoxyribonucleic acid binding protein 2 was determined through the national center for biotechnology information database and the interaction between micro ribonucleic acid-4739 and Ras-related protein 1A was predicted using the starBase and TargetScan databases. T lymphocytes play an important role in immune platelet transfusion refractoriness and long non-coding transactive response deoxyribonucleic acid binding protein 2 may affect the differentiation of T lymphocytes and promote the occurrence of immune platelet transfusion refractoriness through micro ribonucleic acid-4739 targeting Ras-related protein 1A gene regulation.
{"title":"Analysis of the Mechanism of T Lymphocytes Promoting Immune Platelet Transfusion Refractoriness by Gene Chip Technique","authors":"C. Song, Wen Liu, Jing Wang, Jing Liang","doi":"10.36468/pharmaceutical-sciences.spl.671","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.671","url":null,"abstract":"Technique The main objective of this study is to analyze the expression levels of messenger ribonucleic acid and long non-coding ribonucleic acid in patients with platelet transfusion refractoriness and reveal the mechanism of T lymphocytes in immune platelet transfusion refractoriness. The Agilent expression profile chip was used to detect the expression levels; gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis were performed on the differential genes to determine their main biological functions. Unsupervised hierarchical clustering was used to process differential genes and the differential genes among samples were represented in a heat map. The differentially expressed messenger ribonucleic acids and long non-coding ribonucleic acids in different groups were found as 720 and 1719 in normal control group vs. platelet transfusion effective group; 4254 and 12491 in normal control group vs. platelet transfusion ineffective group and 1806 and 6216 in platelet transfusion effective group vs. platelet transfusion ineffective group. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analysis were performed on differentially expressed genes, and the results were annotated to be related to T cells. The co-expression of the target gene Ras-related protein 1A and long non-coding transactive response deoxyribonucleic acid binding protein 2 was determined through the national center for biotechnology information database and the interaction between micro ribonucleic acid-4739 and Ras-related protein 1A was predicted using the starBase and TargetScan databases. T lymphocytes play an important role in immune platelet transfusion refractoriness and long non-coding transactive response deoxyribonucleic acid binding protein 2 may affect the differentiation of T lymphocytes and promote the occurrence of immune platelet transfusion refractoriness through micro ribonucleic acid-4739 targeting Ras-related protein 1A gene regulation.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.693
Ping Tang, D. Xia
Gastric cancer is one of the most common gastrointestinal tumors, annually accounting for about 10 % of all diagnosed cancers and cancer mortalities worldwide. Scutellariae barbata Herba is one of the most commonly used Chinese medicines to treat gastric cancer. Although numerous experiments have been conducted to decipher the mechanism of Scutellariae barbata Herba, it has not been fully elucidated. Therefore, we constructed a pharmacological and molecular docking network to understand the mechanism of action of Scutellariae barbata Herba. The active components and targets of Scutellariae barbata Herba were screened with traditional Chinese medicine systems pharmacology. Gastric cancer related targets were screened using online mendelian inheritance in man and GeneCards Suite database platforms. The intersection target genes of Scutellariae barbata Herba and gastric cancer were retrieved by R software. The Cytoscape software was utilized to draw a drug-compound gene-disease visualization network diagram. The string online analysis platform was incorporated to construct the target-protein interaction network for screening the core targets. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analyses were performed on the core targets. PyMoL and other software were utilized to verify the molecular docking between the key active components of Scutellariae barbata Herba and the key targets. Our results elucidate the active components, associated targets, biological processes and signaling pathways of Scutellariae barbata Herba during gastric cancer treatment. This study deepens our understanding of the potential role of Scutellariae barbata Herba in gastric cancer and provides novel ideas for treating gastric cancer using Scutellariae barbata Herba.
{"title":"Investigating the Mechanism of Scutellariae barbata Herba in the Treatment of Gastric Cancer by Network Pharmacology and Molecular Docking","authors":"Ping Tang, D. Xia","doi":"10.36468/pharmaceutical-sciences.spl.693","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.693","url":null,"abstract":"Gastric cancer is one of the most common gastrointestinal tumors, annually accounting for about 10 % of all diagnosed cancers and cancer mortalities worldwide. Scutellariae barbata Herba is one of the most commonly used Chinese medicines to treat gastric cancer. Although numerous experiments have been conducted to decipher the mechanism of Scutellariae barbata Herba, it has not been fully elucidated. Therefore, we constructed a pharmacological and molecular docking network to understand the mechanism of action of Scutellariae barbata Herba. The active components and targets of Scutellariae barbata Herba were screened with traditional Chinese medicine systems pharmacology. Gastric cancer related targets were screened using online mendelian inheritance in man and GeneCards Suite database platforms. The intersection target genes of Scutellariae barbata Herba and gastric cancer were retrieved by R software. The Cytoscape software was utilized to draw a drug-compound gene-disease visualization network diagram. The string online analysis platform was incorporated to construct the target-protein interaction network for screening the core targets. Gene ontology and Kyoto encyclopedia of genes and genomes enrichment analyses were performed on the core targets. PyMoL and other software were utilized to verify the molecular docking between the key active components of Scutellariae barbata Herba and the key targets. Our results elucidate the active components, associated targets, biological processes and signaling pathways of Scutellariae barbata Herba during gastric cancer treatment. This study deepens our understanding of the potential role of Scutellariae barbata Herba in gastric cancer and provides novel ideas for treating gastric cancer using Scutellariae barbata Herba.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.607
Greys Jimbo, M. Cabezas, Erika Carolina Álvarez Pavón, M. Fernández, Nicole Aguirre
{"title":"Management of Febrile Neutropenia due to Chemotherapy in Latin America: An Evidence-Based Study and Expert Consensus","authors":"Greys Jimbo, M. Cabezas, Erika Carolina Álvarez Pavón, M. Fernández, Nicole Aguirre","doi":"10.36468/pharmaceutical-sciences.spl.607","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.607","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.614
Xiaoyun Tu, Ai-hua Deng, C. Sun, Yang Liu, Yu Chen, Y. Xiong
We aimed to investigate the expression and significance of Epstein-Barr virus-latent membrane protein 1 in human immunodeficiency virus-related diffuse large B-cell lymphomas. 22 cases of human immunodeficiency virus-related diffuse large B-cell lymphomas samples were collected. The control group consisted of 7 cases of non-human immunodeficiency virus-related diffuse large B-cell lymphomas, 6 cases of human immunodeficiency virus-reactive hyperplasia and 6 cases of non-human immunodeficiency virus. The expression of Epstein-Barr virus-latent membrane protein 1 was detected by immunohistochemistry and analyzed in combination with clinicopathology characteristics. The total positive rate of Epstein-Barr virus-latent membrane protein 1 was 77.3 % in human immunodeficiency virus-related diffuse large B-cell lymphomas and 71.4 % in non-human immunodeficiency virus-related diffuse large B-cell lymphomas. Most related diffuse large B-cell lymphomas cells showed nuclear staining pattern and the nuclear positive rate was 82.4 % in human immunodeficiency virus-related diffuse large B-cell lymphomas and 60 % in non-human immunodeficiency virus-related diffuse large B-cell lymphomas. There was no significant difference between human immunodeficiency virus-related diffuse large B-cell lymphomas and non-human immunodeficiency virus-related diffuse large B-cell lymphomas. The expression of Epstein-Barr virus-latent membrane protein 1 was significant between human immunodeficiency virus-related diffuse large B-cell lymphomas and benign lesion. Epstein-Barr virus-latent membrane protein 1 expression in non-germinal center B cell human immunodeficiency virus-related diffuse large B-cell lymphomas was significantly higher than that in germinal center B cell human immunodeficiency virus-related diffuse large B-cell lymphomas. However, Epstein-Barr virus-latent membrane protein 1 expression had no correlation with sex, age, location of tumor and clinical stage (p>0.05). Epstein-Barr virus-latent membrane protein 1 was mainly located in nuclear and overexpressed in human immunodeficiency virus-related diffuse large B-cell lymphomas and non-human immunodeficiency virus-related diffuse large B-cell lymphomas, suggesting that Epstein-Barr virus-latent membrane protein 1 overexpression was involved in tumourogenesis of related diffuse large B-cell lymphomas. Epstein-Barr virus-latent membrane protein 1 expression was correlated with immunophenotype of related diffuse large B-cell lymphomas. As the prognosis was different in different immunophenotype subgroups, Epstein-Barr virus-latent membrane protein 1 may be the potential marker of prognosis for human immunodeficiency virus-related diffuse large B-cell lymphomas.
{"title":"Expression and Significance of Epstein-Barr Virus-Latent Membrane Protein 1 in Acquired Immune Deficiency Syndrome-Related Diffuse Large B-Cell Lymphoma","authors":"Xiaoyun Tu, Ai-hua Deng, C. Sun, Yang Liu, Yu Chen, Y. Xiong","doi":"10.36468/pharmaceutical-sciences.spl.614","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.614","url":null,"abstract":"We aimed to investigate the expression and significance of Epstein-Barr virus-latent membrane protein 1 in human immunodeficiency virus-related diffuse large B-cell lymphomas. 22 cases of human immunodeficiency virus-related diffuse large B-cell lymphomas samples were collected. The control group consisted of 7 cases of non-human immunodeficiency virus-related diffuse large B-cell lymphomas, 6 cases of human immunodeficiency virus-reactive hyperplasia and 6 cases of non-human immunodeficiency virus. The expression of Epstein-Barr virus-latent membrane protein 1 was detected by immunohistochemistry and analyzed in combination with clinicopathology characteristics. The total positive rate of Epstein-Barr virus-latent membrane protein 1 was 77.3 % in human immunodeficiency virus-related diffuse large B-cell lymphomas and 71.4 % in non-human immunodeficiency virus-related diffuse large B-cell lymphomas. Most related diffuse large B-cell lymphomas cells showed nuclear staining pattern and the nuclear positive rate was 82.4 % in human immunodeficiency virus-related diffuse large B-cell lymphomas and 60 % in non-human immunodeficiency virus-related diffuse large B-cell lymphomas. There was no significant difference between human immunodeficiency virus-related diffuse large B-cell lymphomas and non-human immunodeficiency virus-related diffuse large B-cell lymphomas. The expression of Epstein-Barr virus-latent membrane protein 1 was significant between human immunodeficiency virus-related diffuse large B-cell lymphomas and benign lesion. Epstein-Barr virus-latent membrane protein 1 expression in non-germinal center B cell human immunodeficiency virus-related diffuse large B-cell lymphomas was significantly higher than that in germinal center B cell human immunodeficiency virus-related diffuse large B-cell lymphomas. However, Epstein-Barr virus-latent membrane protein 1 expression had no correlation with sex, age, location of tumor and clinical stage (p>0.05). Epstein-Barr virus-latent membrane protein 1 was mainly located in nuclear and overexpressed in human immunodeficiency virus-related diffuse large B-cell lymphomas and non-human immunodeficiency virus-related diffuse large B-cell lymphomas, suggesting that Epstein-Barr virus-latent membrane protein 1 overexpression was involved in tumourogenesis of related diffuse large B-cell lymphomas. Epstein-Barr virus-latent membrane protein 1 expression was correlated with immunophenotype of related diffuse large B-cell lymphomas. As the prognosis was different in different immunophenotype subgroups, Epstein-Barr virus-latent membrane protein 1 may be the potential marker of prognosis for human immunodeficiency virus-related diffuse large B-cell lymphomas.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.685
Aihua Wang, Yongxiang Ma
{"title":"Expression and Clinical Significance of Peripheral Blood Tim3 and Programmed Cell Death Protein 1 in Patients with Colon Cancer","authors":"Aihua Wang, Yongxiang Ma","doi":"10.36468/pharmaceutical-sciences.spl.685","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.685","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69621629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1071
M. Nagasarapu, I. B. Mahammad
{"title":"Validated Bio-Analytical Method for Cinacalcet Concentrations in Rat Plasma by Reversed Phase-High Performance Liquid Chromatography- Photodiode Array Detector Method","authors":"M. Nagasarapu, I. B. Mahammad","doi":"10.36468/pharmaceutical-sciences.1071","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1071","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70215031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.spl.631
Maoliang Chen, Qipeng Tan, Yin Tao, Chun-Yong Wang
{"title":"To Explore Genes Related to the Prognosis of Colorectal Cancer","authors":"Maoliang Chen, Qipeng Tan, Yin Tao, Chun-Yong Wang","doi":"10.36468/pharmaceutical-sciences.spl.631","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.spl.631","url":null,"abstract":"","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69634500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1171
A. Devi, S. Jain, D. Singhal, A. Ghosh, V. Kumar, V. Dwibedi, N. George, Z. A. Khan
Phytoconstituents epigallocatechin gallate and withaferin A, found in Camellia sinensis (Kangra green tea) and Withania sominifera (Ashwagandha) respectively, were explored for their binding affinity towards various enzymes involved in the skin-aging process. Epigallocatechin gallate and withaferin A were analyzed for their physiochemical properties, drug-likeness and human intestinal absorptivity using Data Warrior, Molsoft and SwissADME (boiled egg model) respectively. Molecular docking analysis for different enzymes involved in aging (collagenase, elastase and hyaluronidase), antioxidant enzymes (superoxide dismutase, glutathione-s-transferase, glutathione peroxidase and catalase) and mitochondrial enzymes (nicotinamide adenine dinucleotide (NAD)+hydrogen (H) dehydrogenase, succinate dehydrogenase, cytochrome c oxidase and adenosine triphosphate synthase) was carried out for epigallocatechin gallate alone (1), withaferin A alone (2), epigallocatechin gallate and withaferin A in combination (3) and a reference molecule. Autodock Vina was employed to carry out individual molecular docking as well as multiple ligand simultaneous docking. The results were analyzed in terms of binding energy and different interacting residues. Interestingly, (3) displayed a higher binding affinity towards all the aging and antioxidant enzymes as compared to (1), (2) and the references. Moreover, the combination of the constituents exhibited better binding for most of the mitochondrial enzymes. Additionally, molecular dynamics simulations were performed to estimate stability and flexibility of best complexes, while collagenase activity colorimetric assay was carried out to study the effects of (1), (2) and (3) on collagenase. The in vitro analysis indicated a 1.5 times increase in collagenase inhibition upon using (3) as compared to ascorbic acid (standard). Overall, the results indicate that epigallocatechin gallate and withaferin A, in combination, may potentially inhibit skin-aging, while enhancing antioxidant effects of various enzymes, and warrant further experimental validation.
{"title":"Multiple Ligand Simultaneous Docking Analysis of Epigallocatechin-O-Gallate (Green Tea) and Withaferin A (Ashwagandha) Effects on Skin-Aging Related Enzymes","authors":"A. Devi, S. Jain, D. Singhal, A. Ghosh, V. Kumar, V. Dwibedi, N. George, Z. A. Khan","doi":"10.36468/pharmaceutical-sciences.1171","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1171","url":null,"abstract":"Phytoconstituents epigallocatechin gallate and withaferin A, found in Camellia sinensis (Kangra green tea) and Withania sominifera (Ashwagandha) respectively, were explored for their binding affinity towards various enzymes involved in the skin-aging process. Epigallocatechin gallate and withaferin A were analyzed for their physiochemical properties, drug-likeness and human intestinal absorptivity using Data Warrior, Molsoft and SwissADME (boiled egg model) respectively. Molecular docking analysis for different enzymes involved in aging (collagenase, elastase and hyaluronidase), antioxidant enzymes (superoxide dismutase, glutathione-s-transferase, glutathione peroxidase and catalase) and mitochondrial enzymes (nicotinamide adenine dinucleotide (NAD)+hydrogen (H) dehydrogenase, succinate dehydrogenase, cytochrome c oxidase and adenosine triphosphate synthase) was carried out for epigallocatechin gallate alone (1), withaferin A alone (2), epigallocatechin gallate and withaferin A in combination (3) and a reference molecule. Autodock Vina was employed to carry out individual molecular docking as well as multiple ligand simultaneous docking. The results were analyzed in terms of binding energy and different interacting residues. Interestingly, (3) displayed a higher binding affinity towards all the aging and antioxidant enzymes as compared to (1), (2) and the references. Moreover, the combination of the constituents exhibited better binding for most of the mitochondrial enzymes. Additionally, molecular dynamics simulations were performed to estimate stability and flexibility of best complexes, while collagenase activity colorimetric assay was carried out to study the effects of (1), (2) and (3) on collagenase. The in vitro analysis indicated a 1.5 times increase in collagenase inhibition upon using (3) as compared to ascorbic acid (standard). Overall, the results indicate that epigallocatechin gallate and withaferin A, in combination, may potentially inhibit skin-aging, while enhancing antioxidant effects of various enzymes, and warrant further experimental validation.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1158
S. M. Abdullah, P. M. Mazumder
Pulmonary fibrosis treatment with currently available drugs mostly seems inadequate owing to its progressive and irreversible nature. Persistent activation of underlying mechanisms primarily, oxidative-stress and inflammation in lung leads to pulmonary fibrosis progression and subsequently produces sub-therapeutic control even after prolonged drug therapy. Additionally, due to large dose requirements in the treatment of pulmonary fibrosis unavoidable adverse effects are also an important concern. Thus, alternative drug therapy for pulmonary fibrosis, targeting to the aforementioned chief mechanisms is urgently required. In this view, some phytoconstituents were initially screened for antioxidant and anti-inflammatory activities through in vitro testing. Later, an in vivo study was planned to evaluate and compare the efficacy of two selected compounds namely forskolin (20 mg/kg) and rutin (100 mg/kg), individually and in combination against standard drug pirfenidone (50 mg/kg) using bleomycin-triggered pulmonary fibrosis murine model. Assessment parameters including changes in physical and physiological parameters along with alterations in lung injury markers, oxidative-stress, inflammatory status and fibrotic condition were evaluated during the study. Outcomes of the study exhibited, forskolin and rutin co-administration adequately reversed the physical and physiological changes during pulmonary fibrosis. Besides, it synergistically inhibited biochemical alterations in lung with no significant difference as compared to pirfenidone treatment. Further, forskolin and rutin co-administration showed effectively decline in Szapiel’s and Ashcroft scores and maximally diminish mast cell accumulation than that manifested by pirfenidone in lungs. Overall, efficacy of forskolin and rutin combination against pulmonary fibrosis showed promising potential and hence would contribute in the development of a novel effective treatment regimen in future.
{"title":"Synergistic Effects of Forskolin and Rutin in the Treatment of Pulmonary Fibrosis in Murine Model","authors":"S. M. Abdullah, P. M. Mazumder","doi":"10.36468/pharmaceutical-sciences.1158","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1158","url":null,"abstract":"Pulmonary fibrosis treatment with currently available drugs mostly seems inadequate owing to its progressive and irreversible nature. Persistent activation of underlying mechanisms primarily, oxidative-stress and inflammation in lung leads to pulmonary fibrosis progression and subsequently produces sub-therapeutic control even after prolonged drug therapy. Additionally, due to large dose requirements in the treatment of pulmonary fibrosis unavoidable adverse effects are also an important concern. Thus, alternative drug therapy for pulmonary fibrosis, targeting to the aforementioned chief mechanisms is urgently required. In this view, some phytoconstituents were initially screened for antioxidant and anti-inflammatory activities through in vitro testing. Later, an in vivo study was planned to evaluate and compare the efficacy of two selected compounds namely forskolin (20 mg/kg) and rutin (100 mg/kg), individually and in combination against standard drug pirfenidone (50 mg/kg) using bleomycin-triggered pulmonary fibrosis murine model. Assessment parameters including changes in physical and physiological parameters along with alterations in lung injury markers, oxidative-stress, inflammatory status and fibrotic condition were evaluated during the study. Outcomes of the study exhibited, forskolin and rutin co-administration adequately reversed the physical and physiological changes during pulmonary fibrosis. Besides, it synergistically inhibited biochemical alterations in lung with no significant difference as compared to pirfenidone treatment. Further, forskolin and rutin co-administration showed effectively decline in Szapiel’s and Ashcroft scores and maximally diminish mast cell accumulation than that manifested by pirfenidone in lungs. Overall, efficacy of forskolin and rutin combination against pulmonary fibrosis showed promising potential and hence would contribute in the development of a novel effective treatment regimen in future.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"224 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.36468/pharmaceutical-sciences.1155
S. Kanithi, N. S. S. P. K. Chebolu, G. N. Challa
Favipiravir drug is fitted into antiviral medication criteria and mainly used in the treatment of influenza. The mechanism is associated with choosy inhibition of viral ribonucleic acid-dependent ribonucleic acid polymerase. Development and validation of dissolution method and filter compatibility studies are conducted with reverse phase ultra-performance liquid chromatography method for the quantitative analysis. The validation of this method was performed as per International Council for Harmonisation Q2 (R1) guidelines with the optimized experimental conditions. The proposed method was achieved on Acquity ultra-performance liquid chromatography HSS C18 (100 mm×1.8 μ) column and temperature maintained at 30° and run time was 8 min. The mobile phase consists of A-Methanol, B-0.1 % Trifluoroacetic acid (v/v) in water (pH=4.8). The injection volume of samples was 1 μl and ultraviolet detection was carried out at 210 nm. Linearity ranges were covered from 1 % to 300 % of the sample concentration level. The newly developed dissolution profile will show good repeatability and reproducibility in solid dosage forms and proved the filter compatibility studies. The projected method has capable to produce swift retention time and maintained well percentage recoveries throughout the dissolution profile. Hence this method can be used in customary quantitative analysis in quality control department for solid dosage forms and active pharmaceutical ingredients.
{"title":"Development and Validation of Favipiravir Severe Acute Respiratory Syndrome Coronavirus 2 Drug by Dissolution Method with Filter Compatibility Study","authors":"S. Kanithi, N. S. S. P. K. Chebolu, G. N. Challa","doi":"10.36468/pharmaceutical-sciences.1155","DOIUrl":"https://doi.org/10.36468/pharmaceutical-sciences.1155","url":null,"abstract":"Favipiravir drug is fitted into antiviral medication criteria and mainly used in the treatment of influenza. The mechanism is associated with choosy inhibition of viral ribonucleic acid-dependent ribonucleic acid polymerase. Development and validation of dissolution method and filter compatibility studies are conducted with reverse phase ultra-performance liquid chromatography method for the quantitative analysis. The validation of this method was performed as per International Council for Harmonisation Q2 (R1) guidelines with the optimized experimental conditions. The proposed method was achieved on Acquity ultra-performance liquid chromatography HSS C18 (100 mm×1.8 μ) column and temperature maintained at 30° and run time was 8 min. The mobile phase consists of A-Methanol, B-0.1 % Trifluoroacetic acid (v/v) in water (pH=4.8). The injection volume of samples was 1 μl and ultraviolet detection was carried out at 210 nm. Linearity ranges were covered from 1 % to 300 % of the sample concentration level. The newly developed dissolution profile will show good repeatability and reproducibility in solid dosage forms and proved the filter compatibility studies. The projected method has capable to produce swift retention time and maintained well percentage recoveries throughout the dissolution profile. Hence this method can be used in customary quantitative analysis in quality control department for solid dosage forms and active pharmaceutical ingredients.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135360669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}